Get started

Coronavirusstocks

Can the New FDA Nod of Approval Push Gilead to New Highs U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus. From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation. We expect Gilead to push higher with this recent news coupled with it Beating Earning Expectations for Q1 2020. This stock isnt a value stock with a PE of 18x and a Price to Book of 4x but it isn't overly expensive considering its growth potential (PEG 5yr 0.57).
NASDAQ:GILDLong
by Tuhi_Capital
GILD Analysis ||| it's a short term buy (2-5 months)The GILD price fold into the inside pitchork channel on the long term. This signal a long term downtrend, which does not serve visionary long term investment. However, for the intermediate term analysis. GILD price follow channel patter as is in the second channel. Despite the extraordinary selling volume, the price found a strong support at 75$. GILD next TP needs to be positioned at 89$. If the price breaks the 89$ resistance with momentum, the next TP is at 103$.
NASDAQ:GILDLong
by UTOMAN
MMM; Has Coronavirus helped 3M enough to keep them above water?!MMM; Has Coronavirus helped 3M enough to keep them above water?! ✨ We provide charts every day ✨ Like and Follow to help us grow family! 🎉 --- Let's Go! Time to see the much-anticipated earnings report from our savior 3M. We are hoping they are good and the chart may show this first hand already! --- 1. Fractal Trend showing an uptrend (Green background color) for MMM on the 1 hour chart. We are hoping this is not a false breakout like we saw previously. 2. We are currently in a quite parabolic move to the upside, thankfully we have a trailing stop riding behind this move to attempt to lockin as much profit as possible. 3. We are looking for a reaction at the R1 bearish orderblock where we hope to see Breakaway Scalper go neutral so we can get in on this tear! 4. If R1 can't hold, we will be looking at R2 and R3 as expected resistance going forward. 5. S1, S2, and S3 are all acceptable levels we are keeping an eye on but any lower and well... you guys know the rest.
NYSE:MMM
by AlphaBotSystem
SIM.V -- Supplying communications equipment to first respondersTook SIM @ .13. Under the radar play. Supplying military & first responders with communications equipment. Operating as essential business during the pandemic. Oversold and hit 52 wk low at .125 today. Scored some good contracts recently. -------------------------------------------------------------------------------------------------------------------------------------------- Siyata Mobile Launches UR5 Rugged Smartphone Device for the Enterprise and First Responder Mobile Workforce “Rugged and Ready” the UR5 Handles the Most Vigorous Mobile First Responder and Workforce Environments MONTRÉAL, April 27, 2020 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (TSX-V:SIM / OTCQX:SYATF/ FRA: WK3D) is pleased to announce the launch of the 4G/LTE UR5 rugged device for the first responder and enterprise mobile workforce. The UR5 is “Rugged and Ready” to handle the most vigorous work environments encountered by enterprise workers and first responders on the front line of defense. The UR5 is an ultra lightweight, handheld rugged Android smartphone, with integrated Push-To-Talk (PTT) and the ability to easily switch PTT channels with its unique rotary channel selection knob to navigate various PTT groups. With a dedicated SOS button, first responders can immediately signal an emergency on a broad scale with a single touch of a button which meets “Alyssa’s Law” protocol.* The UR5 comes with an IP68 Mil Spec rating for protection against liquid, dust, drops and other physical shock. The device also boasts a unique connector which allows to physically connect a PTT headset to the device without the worry of the headset falling out when workers or first responders are on the move. The UR5 can be integrated with third party Command & Control software which allows medical units (and other land forces) to speak to entire teams; displaying their real-time locations and their zones of operation; visually categorizing hospital beds according to severity; and uses artificial intelligence to automatically manage workloads, identifying teams that are inactive and allocating them to where they are needed most. The current COVID-19 crisis is making hygiene essential to front line workers and to minimize risk of infection, the UR5 can be rigorously cleaned and disinfected with soap, water and other sterilizing liquids or solutions, time and time again. When equipped with the UR5, vehicle drivers can stay connected, in real time to its various designated PTT groups, even while they are outside of the vehicle making this a highly complementary device to Siyata's in-vehicle portfolio and cellular booster systems. Marc Seelenfreund, CEO of Siyata states, “We are very excited to be launching our next generation UR5 rugged device. It is a highly complementary product to our unique in-vehicle and cellular booster portfolio and gives our target market a complete offering for first responders and enterprise workers. The UR5 rugged device enhances our sales opportunities, without the need for additional sales staff, as we empower them with more critical communication devices to sell through our carrier and distribution partners to the end customers.” UR5 Rugged Device Features: IP68 rating for protection against liquid and dust Mil spec- 810G rating for protection against drops and other physical shock Android Operating System for access to thousands of apps Dedicated physical SOS button for immediate emergency alerts Integrated with leading PTT applications for instant communication to groups or individuals at the push of a large, physical PTT button Unique rotary channel selection knob, to easily navigate PTT groups Extra loud speaker and extended battery life 2.8” LCD touch display with glove mode operation Front and Rear cameras to capture video and photographs during crisis Supports hands free bluetooth for no-touch communication *Alyssa’s Law would require K-12 Public Schools across the United States to have a panic alarm that is linked directly to local law enforcement. Alyssa’s Law is critical legislation addressing the issue of law enforcement response time when a life-threatening emergency occurs because time equals life. The law calls for the installation of silent panic alarms that are directly linked to law enforcement, so in case of any emergency they will get on the scene as quickly as possible, take down a threat and triage any victims. About Siyata Siyata Mobile Inc. is a B2B global vendor of next generation Push-To-Talk over Cellular (PTT) devices and cellular booster systems. Its portfolio of in-vehicle and rugged smartphones enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to improve communication, increase situational awareness and save lives. Its portfolio of enterprise cellular booster systems enables first responders and enterprise workers to amplify its cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for maximum cellular signal strength possible. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.
SLong
by wealth_bakery
2
IMMUCELL: $5.17 Short Target + Watchlist PotentialFirst off don't take anything I say seriously or at face value, this is an opinion basis. As always, I could be wrong. That being said, let us get into the analysis. Doing a fibonacci-based analysis, I think a conservative medium risk target of $5.17 within the next upcoming weeks is feasible. I also think Immucell could have bullish retracement potential from its previous negative correlations last quarters. This means, it may be worth holding on to for a long position as well, but I would need to do more research before being personally confident. Definitely though, a stock on the watchlist. Giving calves immunity for E. coli, coronavirus and rotavirus, as they are hoping, would be high in demand right now. This is for obvious reasons. If there research goes somewhere, it is better to be safer then sorry with food resources. Especially if they get approved processes and end up being bioethically permissible.
NASDAQ:ICCCShort
by gamer456148
Biontech AG Outbreak - First COVID-19 human vaccine trial test Hey fellow Trader, The uprising Biotechnology company from NASDAQ:BNTX Mainz, Germany is on its final steps from developing a vaccine for the actual Bio-weapon health crisis from the "new flu" . With Rolf Zinkernagel a brilliant Scientiests that can proudly say to win a nobelprice and a strong financial background , from big names in the Pharmaceutical field. When BioNTech AG announced to start with the first human vaccine tests after getting an approval in Europa , a US approval should follow shortly after also. We should expect News from those test in end May/june and if they´ve managed to create a proven vaccine afterwards im staying LONG in this Outbreak because its Trending and the Chances are high for a good R/R. A Golden Cross is forming and the Overall Stock is positive and with a low beta so less correlation risk in this given "Crazy Market" . So with a break of the 56 level we should see a strong move up. Goals are high and i think it could touch the 100 mark again with reactive move down to given support levels if they arent successful with their vaccine Therapy. STOPLOSS tight at 49,45 I hope this was helpful but it only displays my opionion and no financial adivce is given here. Sincerly, Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
1
DOC.C - Telemedicine services in high demand during the pandemicCloudMD Reaches Over 100,000 Registered Users on Telemedicine Platform VANCOUVER, British Columbia, April 07, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has reached over 100,000 registered users combined on its CloudMD and MyHealthAccess telemedicine platforms. To date, CloudMD has grown its platform of registered users organically and a large part of its customer acquisition has come from referrals from its network of doctors in Canada. Patients on both platforms have easy access to the extended hours, 7 day week coverage provided by the CloudMD doctors. Since its launch in February 2020, CloudMD has grown its platform by almost 10,000 app downloads. During the last two weeks, approximately 1000 virtual doctors appointments were booked on the CloudMD platform, growth of over 3x compared to the previous period. Combined registration on both platforms have also increased 133% over the last week, as more people remain in isolation and cannot attend in-person medical appointments. With the recent COVID-19 pandemic, CloudMD offers Canadians an alternative to in-person visits to crowded or closed medical clinics. Patients can now download the CloudMD app and schedule a same day appointment online and connect directly with a licensed physician on their phone, tablet, or computer from the comfort of their home. Dr. Essam Hamza, CEO of CloudMD commented, “CloudMD continues to revolutionize the way healthcare is delivered to patients. We are excited and encouraged by the continued growth of our CloudMD platform as the significant increase in registered users continues to reinforce buy-in from the communities we serve.” He continued, “During these difficult times we are proud to offer much needed and timely medical care to the Canadian population. We remain committed to providing the best health care services to our patients.” CloudMD also announces it has engaged Strike Communication Inc. (“Strike”) to manage investor relations and corporate development strategies. Strike is a boutique capital markets advisory firm based in Vancouver, BC. As part of its compensation, Strike will be granted incentive stock options exercisable to purchase up to 150,000 common shares in the capital of the Company at an exercise price of $0.50 per share for a period of five years. 100% of the incentive stock options will vest 12 months after the grant.
DLong
by wealth_bakery
MBX.TO -- Attains Health Canada License for COVID-19 TestingMicrobix Attains Health Canada Establishment Licensing MISSISSAUGA, Ontario, April 21, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator and exporter, announces that it has attained medical devices establishment licensing from Health Canada, enabling the immediate usage of its quality assessment products (QAPs™) by clinical laboratories, including its QAPs to help ensure the accuracy of COVID-19 disease testing. It has been widely reported that the recently-deployed tests for the virus causing COVID-19 disease are providing results of questionable accuracy – sometimes giving “false negative,” or “false positive” results. Microbix’s QAPs are designed to increase the reliability of test results and this licensing from Health Canada will allow their use in testing labs across the country. At present, Microbix has capacity to make 5,000 units per week of room-temperature stable COVID-19 QAPs exclusively on COPAN® FLOQSwabs®, and 10,000 units per week in a liquid vial format. Such QAPs can be shipped as early as April 30 to support the verification of new testing methods, the validation of newly-placed test instruments, training of technicians, lab proficiency accreditations, and by clinical labs for systematic quality control. By way of example, at usage of one per hundred tests, such QAPs can help ensure the accuracy of 1.5 million COVID-19 tests per week. Cameron Groome, President and CEO, stated, “We thank Health Canada for its review and acceptance of the application provided by Microbix on April 13th. Such prompt action is precisely what is needed to get leading-edge tools like Microbix’s QAPs into the hands of Canada’s front-line healthcare providers. Microbix will now engage with procurement authorities in Ontario and other provinces and territories to make certain that Canadians can benefit from Microbix’s products that help to ensure test accuracy.” The Microbix COVID-19 QAPs have been shown to work with multiple nucleic-acid based test (NAT) methods used to detect the SARS-CoV-2 virus that causes COVID-19 disease, specifically those targeting E, N, and RdRP genes, and on protocols requiring human RP housekeeping gene presence. These Microbix products are being made available as REDx™FLOQ® SARS-CoV-2 for swabs, and as REDx™ SARS-CoV-2 for liquid aliquots. As for all Microbix QAPs, these COVID-19 QAPs are whole-genome workflow support tools that include 100% of the genetic sequences of the virus and emulate real patient samples while being consistent, non-infectious, and stable. As such, the COVID-19 QAPs contain all possible NAT viral targets – ensuring compatibility across current and future NATs. This broad compatibility and guaranteed utility is particularly relevant in the context of testing during a pandemic, when multiple test protocols and instrument systems are being newly-called into use. Microbix supplies a broad range of white-labeled QAPs, including other viral respiratory pathogens, to support the proficiency testing (PT) programs of laboratory accreditation organizations in North America and Western Europe. Under its PROCEEDx™ brand, Microbix provides RUO (research-use-only) QAPs to support the test validation/verification and operator training objectives of test developers and clinical labs. Full QMS support of clinical laboratory patient sample testing is provided by Microbix’s Health Canada licensed, FDA registered, and CE mark certified REDx™ Controls or REDx™FLOQ® brand QAPs. About Microbix Biosystems Microbix develops proprietary biological and technology solutions for human health and well-being, with approximately 80 skilled employees and sales now usually exceeding $1 million per month on average. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests. Microbix antigens and QAPs are sold to many customers worldwide, at present primarily to multinational diagnostics companies and laboratory accreditation organizations. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is a publicly-traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.
TSX:MBXLong
by wealth_bakery
NSP.V -- Ensuring food supply in BC during Coronavirus outbreakNSP.V is helping to ensure stable food supply in BC and has applied for government funding to retool and to up its production. Also offering natural anti-viral and anti-bacterial supplements based on curcumin that may help in preventing spread of COVID-19. The stock is cheap at $4.24 M and is reversing after prolonged downtrend. Bottom .025 has been tested and held multiple times. Buyers are stepping in in recent days as confirmed by bullish MACD cross and RSI/Stoch action. Very good chance of a bounce from current levels (.03), IMO
NLong
by wealth_bakery
2
GGG.V -- Air filtration equipment to fight spread of virusesPulled out of overbought area and filled the gap. Fib. support at .09. Strong volume. I am in at .09. --------------------------------------------------------------------------------------------------------------------------- G6 Materials Corp. Develops Disinfection Products to Fight the Spread of COVID-19 April 1, 2020 - TheNewswire - Ronkonkoma, NY USA - G6 Materials Corp (the "Company" or "G6," (TSXV:GGG) (OTC:GPHBF) is pleased to provide an update from its Research & Development department. The outbreak of the COVID-19 has drastically altered the economic landscape, and G6 management is optimizing the business model to accommodate the new reality, addressing these new business opportunities. The CEO of the Company, Daniel Stolyarov, explains, “There is an imminent demand for solutions that allow for the removal of viruses from the air and surfaces increasing the safety of the immediate environment. The Company has prioritized work in this sector and plans to address these market needs immediately.” The Company's Research & Development Department has developed a solution for air purification products that are designed to mitigate the threat of virus infection in confined spaces such as offices and industrial warehouses. There is substantial scientific evidence of antiviral and antibacterial effectiveness of graphene coatings. The Company has found a unique method to incorporate graphene in the air filtration systems making them more efficient in killing germs. The Company is currently conducting internal testing, and will subsequently apply for appropriate accreditations. The applications of this solution are numerous. Such systems can be included in existing HVAC systems or included in the design of new ones. They can be combined with conventional filtration methods as well as UV irradiation. Any large scale structures, including office buildings and factories, could all be the benefactor of this system. Stolyarov continues, “Economies all around the world are experiencing unprecedented disruption due to the COVID-19 situation, leaving a long-lasting impact. We hope that the quarantine measures prove effective in stemming the spread of the virus, but quarantines cannot last forever. When people return to work they will demand that their work environment is safe. We provide a solution to this problem". The Company will continue testing of the prototypes and is actively looking for an industrial partner to rapidly expand the manufacturing capability and bring these highly demanded products to market.
TSXV:GGG
by wealth_bakery
IPA.V - Agreement with Johnson & Johnson for Coronavirus vaccineIPA.V appears to have entered into agreement with Johnson & Johnson's subsidiary to develop the Coronavirus vaccine. The market is asleep due to cryptically worded news release. Connecting the dots... --------------------------------------------------------------------------------------------------------------------------------------- ImmunoPrecise Announces Agreement with Janssen VICTORIA and CAMBRIDGE, MA, April 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen"), providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the Agreement, Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed. "This Agreement validates Talem's business concept in early antibody discovery and development," said Ilse Roodink, Chairwoman of Talem's Scientific Advisory Committee and Scientific Director at IPA Europe. "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications." "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America," added Jennifer Bath, President and CEO of IPA. --------------------------------------------------------------------------------------------------------------------------------------- The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine. That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other firms have. The deal was signed with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) on March 27, 2020. It followed another order, made as part of the same contract with Janssen, for $150 million on March 20, 2020, for a “new antiviral” for COVID-19. A spokesperson from Johnson & Johnson didn’t provide any more details on the specific order, but confirmed the $456 million award related to a collaboration with ASPR’s Biomedical Advanced Research and Development Authority (BARDA), as announced in February. That work was built on previous contracts for developing countermeasures for other influenzas. The value of the coronavirus-specific work hadn’t previously been revealed and is the largest known contract for a coronavirus vaccine to date. It forms part of a deal between the U.S. government and Johnson & Johnson to co-invest $1 billion into vaccine research, development and clinical testing. The company says it now expects human clinical studies for its vaccine candidate to go ahead, at the latest, by September 2020. It anticipates the first batches of vaccine to be available for emergency use in early 2021.
ILong
by wealth_bakery
1
GSI.V Video systems for smart cities; essential business statusStrong accumulation. Bullish MACD cross. Bullish Stoch/RSI action. I am in at .15. --------------------------------------------------------------------------------------------------------------------- Gatekeeper Operating as Essential Business During COVID-19 Outbreak Abbotsford, BC - TheNewswire - April 6, 2020 - Gatekeeper Systems Inc. (‘Gatekeeper’ or the ‘Company’) (TSXV:GSI) (OTC:GKPRF) (FSE:1GK) a leading provider of intelligent video solutions for public transport and smart cities, provides a corporate update relating to its operations during the COVID-19 outbreak. Gatekeeper, through its subsidiary Gatekeeper Systems USA Inc., has been deemed an essential business during the emergency order which temporarily prohibits operation of non-essential businesses in Pennsylvania. The Company’s business relating to the Southeastern Pennsylvania Transportation Authority (SEPTA) continues normal operations. SEPTA is the Company’s largest customer and represented approximately 30% of the Company’s revenues during its 2019 fiscal year. The Company reports no material change in its contract with SEPTA announced on October 17, 2019 to provide annually recurring services valued at approximately $2.36 million per year. The Company reports no material change in its contract with SEPTA announced on October 9, 2019 to supply and install digital video recorders on SEPTA vehicles and trains in a contract valued at approximately $6.3 million. This contract is expected to be billed during the second half of the Company’s fiscal year which ends August 31, 2020. Gatekeeper has adjusted its business operations during the COVID-19 outbreak to firstly ensure the safety of its employees as its top priority. Protection procedures for service technicians have been implemented and office employees are working from home where possible. The Company is also working with its suppliers and customers during this period of business disruption to ensure continuity of business operations where possible. The Company will report its financial results for its second quarter ended Feb 29, 2020 by the prescribed filing due date of April 29, 2020. Gatekeeper also announces that it has granted an aggregate of 675,000 incentive stock options to certain directors, officers, employees and consultants under the Company’s stock option plan, subject to regulatory approval. The stock options are exercisable at a price of $0.135 for a period of five years from the date of grant and subject to vesting provisions.
TSXV:GSILong
by wealth_bakery
What will happend to this second breakout? It seems like the price is trading on sentiment right now. The Positives : There is talk that the curve has been suppressed. The worst in Spain and Italy seem to be over. Austria is looking to relax the lockdown. The Fog : However, we miss fundamental news. That, if you know more about please let me know. How soon will the airline be allowed to operate again? And where will they be allowed to fly to? Will there be an effect on how many roundtrips can do due to more strict security measures. What will demand be for airline travel? How long did it take for airline travel to be back to normal after 9/11 ( I think quite some time). Are they in need of a bailout? If yes, who will pay for it? Will there be one for all EU airlines? Range: The 52 week high is 16 I think it will take quite some time before we go back to that high. Read "This stock will not pop overnight"
XETR:RY4C
by RabbiJacob
1
The start of a huge bull run in BTC again?Patterns and price action repeats itself over and over again in markets. Time and time again we see assets with their own specific price action characteristics repeating which can present us with fantastic opportunities to get into the market. Here you see BTC price action (blue) in 2015 following the LTC (Litecoin) halving which led to a bull run that reached $20,000. The price action is strikingly similar to the current BTC price action after the 2019 LTC halving with one major difference: we have encountered an enormous unforeseen deflationary spike as a result of the Coronavirus pandemic which has led to a hefty drop in BTC price. Just before this deflationary spike, BTC was following an upwards trend to the 10,500 mark which in visual terms matched almost precisely what happened in 2015 (check the comparison of price action). With the Federal Reserve flooding the markets with liquidity and massively increasing the circulation of dollars in the system to try and inflate our way out of this crisis, I find it hugely improbable that the markets will suffer any more drops of significance which leads me to believe that BTC will continue on its original path upwards. With the purchasing power of the USD set to fall off in light of the Fed's mass printing, this will push prices in BTC higher and with a shortage of the only other tangible and unprintable assets on earth (commodities ) it is my belief that considerable amounts of money will enter Bitcoin and the crypto space in general, therefore, price action will continue in its original path.
BITFINEX:BTCUSDLong
by jakecarling41
7
30 Days Later – Italy vs. USAs the Coronavirus continues to spread throughout the globe without any cure or treatment, researchers have been left with nothing but data to help predict and counter the disease. This being a novel virus, even our data sets are tremendously lacking. We must make do with what we have, and 4 months into this global pandemic it seems that Italy has been taking the blunt of this disease; Creating a benchmark for other countries to compare. There are numerous articles out there comparing the United States to Italy, many of which only compare the total number of cases. Based on that factor alone, the US is in far worse shape than Italy being approximately 8 days behind on the outbreak. At the time of writing this article, Italy is at 110,574 cases while the US is nearly doubled at 209,071 cases of the COVID-19 virus. Comparing the two countries should not end at the total number of cases. There are far more ways to analyze the available data to see how the United States and other countries compare using Italy as a precedent. Population Factors One of the largest factors to consider are the two counties populations. Italy’s population is ~60.5 million people while the United states is over 5 times the size at about ~330 million. Right there you can see that comparing the two countries based on the number of cases is not enough. The case comparison above shows the total percentage of the country’s population affected by the coronavirus. Offsetting Italy by 8 days, you will see that the United States is fairing much better when it comes to the total percentage of the population affected. Using Italy as a precedent, Day 33 of the outbreak Italy was at 0.123% of their total population infected, while the United States was at 0.074%. Today Italy is at 0.19%. Transmission Rate Based on the total percentage of the population, the data shows that Italy is in far worse shape than the United States. However, this could change at any time based on how quickly the disease is spreading throughout each country and how each country manages the spread. The Transmission Rate is generated by the number of new cases each day compared to the day before. Looking at transmission rate data above, you can see that the United States has been greatly higher than Italy over the last two weeks. Though the US transmission rate seems to be dropping a considerable rate, it is still at 14.1% compared to Italy’s 4.2% which seems to be leveling off. Getting this factor as low as possible will be key to controlling the spread around the globe. Breaking the data down, the chart below shows the number of new COVID-19 cases, recoveries, and deaths per day between Italy and the United States. Looking at this data we can determine that Italy’s number of new cases seems to be dropping each day from their peak on March 22. This shows that the measures the country is taking to battle the Coronavirus could be working. IF the United States similar measures as Italy, they should start to see a decline in the number of transmissions per day. “Flattening the curve” to say. Mortality Rate One of the scariest data sets to compare is the COVID-19’s mortality rate. Currently the United States has a 2.55% mortality rate which is well below the global average of 5.23%. These factors are based on confirmed cases and deaths. Italy, however, is at a whopping 12.25% mortality rate. Meaning more than 1 out of 10 people who contract the disease is expected to die. The most chilling thing about this is that all three averages have been increasing each day. Clearly after seeing these values we can see that the United States is fairing off much better than Italy for the time being. Knowing this, there are three major factors to consider: This data is based on ‘Confirmed’ cases and deaths. Meaning there could be numerous positive COVID-19 cases that have not been tested. Italy’s median age is significantly higher than the United States. Unfortunately, this disease is known to target older, immuno-compromised adults. The United States is 8 days behind Italy, meaning only a small percentage of the current Covid-19 cases have had time to mature enough to result in an outcome. Therefore it is possible to see a sudden increase in this value. Recovery Rate This data is petrifying, however, there is some light at the end of the tunnel. Recovery rates around the world are on the rise. Currently it is estimated to take 2-3 weeks to recover from this disease, meaning the current data available is only a small reflection of what has yet to come. The chart below shows both Italy and the United States’ recovery rates as of today. Italy being 8 days ahead of the US, has a significantly higher recovery rate. Within the coming months I expect both values to increase greatly, better reflecting true recovery rate of COVID-19. I would like to thank TradingView for making the COVID-19 data available on their platform. This has allowed script writers like myself to break the data down, analyze, and share information through this global pandemic. During this global pandemic, there is limited information available on the COVID-19 disease itself. However one thing we do have is data; and we get more of this every day. The indicator referenced in this article will be made available to the public so that you can tract this data in real time. You will find it under the scripts tab on my profile page. *Case comparison is based on the previous days data.
D
by oh92
12